Injectsense Inc.

We are excited to announce a $1.7M SBIR award for our IOP for . Last month's grant from the NEI covers solid state microbattery integration and testing of our ultra-miniature autonomous devices (shown in carrier below). Testing to be managed by Johns Hopkins' Wilmer Eye Institute. Human pilot study scheduled for later this year. https://bit.ly/3vuQxHv

The IOP data from this monitoring system is directly transmitted from the eye to a mobile phone, and then the cloud. This enables physicians to get alerts about clinically actionable fluctuations in IOP.

We are in complete agreement with Dr. Bedrood. We feel that IOP requires continuous 24 hour monitoring through a sensor, to reduce the risk of vision loss and improve the quality of life for glaucoma patients.

In-vivo sensing devices are at the heart of digital health, and will collect real-time data that can assist doctors during telehealth visits during times such as these. Injectsense’s implantable iOP-Connect is smaller than a grain of rice and measures IOP 24/7 over years.